Catalyst Biosciences (CBIO) Coverage Initiated at B. Riley
Research analysts at B. Riley started coverage on shares of Catalyst Biosciences (NASDAQ:CBIO) in a report issued on Friday, MarketBeat.com reports. The brokerage set a “buy” rating and a $19.00 price target on the biopharmaceutical company’s stock. B. Riley’s price objective indicates a potential upside of 151.99% from the company’s previous close.
Separately, Zacks Investment Research raised shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Wednesday, November 8th.
Catalyst Biosciences (NASDAQ:CBIO) traded up $0.39 during trading hours on Friday, hitting $7.54. 887,443 shares of the stock were exchanged, compared to its average volume of 453,393. Catalyst Biosciences has a 12 month low of $3.11 and a 12 month high of $21.30.
ILLEGAL ACTIVITY WARNING: “Catalyst Biosciences (CBIO) Coverage Initiated at B. Riley” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/08/catalyst-biosciences-cbio-coverage-initiated-at-b-riley.html.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
Receive News & Ratings for Catalyst Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.